Impax Inks $33M Deal With Investors In Price-Fixing Suit
A proposed class of Impax Laboratories Inc. investors asked a California federal judge to preliminarily approve a $33 million settlement that would resolve claims the generic-drug maker failed to disclose a...To view the full article, register now.
Already a subscriber? Click here to view full article